Metropolis Q2FY26 Growth Highlights

  Published 6 months ago

Metropolis Healthcare posted strong Q2FY26 growth across diagnostics, wellness, B2C, and B2B segments with profitability.

  • Core Diagnostics, Scientific Pathology, Agra, DAPIC, and TruHealth drove 25‑36% YoY segment growth across segments.
  • B2C revenues rose 16% YoY; B2B surged 34% thanks to core diagnostics expansion in 2025.
  • Acquired Ambika Pathology, adding Kolhapur presence; the company remains debt‑free with Rs 55 crore cash and growth.

You might like these

D-Mart Q2 FY26 Growth Highlights

Angel One: May 2025 Performance Snapshot

GRSE Wins Defence Contract, Shares Rise

Q1 Earnings: Key Stocks in Focus Today

Titan Intech Joins MIC for Mini-LED Tech

Voltas Shares Slip Amid Weak AC Demand

CEAT Q1 Margins Fall, Expansion Planned

News that matters the most ⚡